the "Company†), a world-leading manufacturer of high-end, medically certified cannabis vaporizers and a subsidiary of Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC), today unveiled the VEAZY— an accessible new addition to its premium portfolio, extending the Company's precision engineering to a broader audience. The VEAZY delivers an uncompromising solution, designed to be as approachable as it is easy t. TUTTLINGEN, Germany--(BUSINESS WIRE)--STORZ & BICKEL GmbH ("STORZ & BICKEL†or ...

3 Canadian Cannabis Stocks to Watch Closely This WeekInvestors are closely watching Canadian cannabis stocks this week amid rising U.S. industry momentum. The U.S. cannabis market hit an estimated $38.5 billion in 2024 and may grow at a compound annual growth rate (CAGR) of about 11–12 percent through the late 2020s. Meanwhile, several states are advancing reform. Notably, Delaware began adult-use cannabis sales on August 1, 2025. Moreover, at the federal level, the Trump administration signaled plans to re ...

Industry Overview - The cannabis sector has faced a prolonged slump due to the lack of federal reforms, but recent comments from President Trump regarding marijuana rescheduling have sparked renewed optimism, leading to a surge in share prices [1] - A potential federal reclassification could significantly transform the industry by easing tax burdens, improving access to banking services, and facilitating broader medical and recreational adoption, with the market expected to exceed $160 billion by 2032 [2] Company Analysis: Village Farms International (VFF) - Village Farms International holds a Zacks Rank 1 and is one of the few cannabis operators consistently generating positive EBITDA and cash flow, with Q2 earnings showing a 690% year-over-year increase in international medical export sales [4][6] - The company has divested its lower-margin fresh-produce business to focus on higher-margin cannabis operations, maintaining its position as one of Canada's top three cannabis players and contributing $2.4 million in incremental Q2 revenues from shipments to the Netherlands [5] - EPS estimates for VFF have improved significantly, with 2025 estimates rising from a loss of 9 cents to earnings of 12 cents, and the stock has increased nearly 274% year to date [6] Company Analysis: Canopy Growth (CGC) - Canopy Growth, with a Zacks Rank 2, has been streamlining operations by exiting lower-margin businesses and selling non-core assets to enhance liquidity and reduce operating expenses [7] - The company's U.S. strategy through Canopy USA provides exposure to key recreational and medical cannabis markets, and federal rescheduling could accelerate the commercialization of its U.S. assets, creating new revenue streams [8] - Loss per share estimates for CGC have narrowed from 57 cents to 50 cents for 2025, and despite a 55% decline in stock price year to date, improvements in top- and bottom-line metrics are encouraging for investors [9] Company Analysis: High Tide (HITI) - High Tide, also holding a Zacks Rank 2, is recognized as one of Canada's fastest-growing cannabis retailers, operating over 170 branded retail locations and leveraging both physical and online sales channels [10] - Loss per share estimates for HITI have improved from 5 cents to 4 cents for 2025, with 2026 EPS rising from 5 cents to 11 cents, and the stock has seen a 9% increase, driven by strong operational performance and optimism regarding federal marijuana rescheduling [11][12]

Group 1 - The U.S. industrial hemp sector showed strong performance on Monday, with notable gains in several companies [1] - Tilray (TLRY.US) increased by over 8.9%, OrganiGram Holdings (OGI.US) rose by more than 6%, and Sundial Growers (SNDL.US) climbed nearly 4% [1] - Aurora Cannabis (ACB.US) saw an increase of over 2.6%, while Canopy Growth (CGC.US) surged by more than 6.5% [1]

Core Insights - Canadian cannabis firms with U.S. exposure are gaining attention due to their ability to bridge both markets, which positions them advantageously as U.S. policy shifts may provide new momentum for growth [1][2][24] - The U.S. legal cannabis market is projected to grow from approximately $37 billion in 2024 to over $91 billion by 2033, indicating a strong annual growth rate of more than 10 percent [2][24] - Recent headlines regarding potential federal reclassification of marijuana have fueled optimism, leading to a rally in cannabis stocks as traders seek follow-through momentum [3][24] Company Summaries Tilray - Tilray is one of the largest cannabis companies globally, focusing on cannabis-adjacent consumer goods in the U.S., with its beverage division being a key growth driver [5][6] - The company reported annual revenue exceeding $820 million, but also a significant net loss of over $2 billion, highlighting the need for tighter cost control despite strong performance in certain divisions [9][11] - The beverage segment achieved gross margins of around 40 percent, indicating strong consumer demand and pricing power [10] Village Farms International - Village Farms operates large-scale greenhouses, supplying cannabis in both Canada and the U.S., with a focus on efficient production rather than retail [12][14] - The company emphasizes wholesale supply to licensed retailers, which reduces capital costs and lowers risk while controlling significant production volumes [12][14] - Recent financial results show steady progress, with Canadian cannabis sales increasing year over year, benefiting from rising demand and improving margins [15][16] Canopy Growth - Canopy Growth is known for its broad product portfolio, including flower, pre-rolls, edibles, and wellness products, and has a presence in the U.S. through licensing and partnerships [17][20] - The company reported strong growth in Canadian medical cannabis sales, reaching $77 million, while international sales showed slight declines [21][22] - Canopy's gross margins expanded by 300 basis points year over year, and it reduced total debt by nearly 50 percent, indicating progress in strengthening its balance sheet [21][22] Market Outlook - The U.S. cannabis market's expansion presents significant opportunities for Canadian firms with U.S. exposure, particularly as potential rescheduling of marijuana could reduce restrictions and enhance valuations [2][24] - Volatility in the sector remains high, making technical analysis and risk management essential for investors looking to participate in the growth story [4][25]

Core Viewpoint - Canopy Growth (NASDAQ: CGC) experienced a 24% increase in stock price following President Trump's announcement regarding the potential rescheduling of cannabis in the upcoming weeks, indicating a significant opportunity for expansion into the U.S. cannabis market [1]. Group 1: Company Insights - Canopy Growth is strategically positioned to expand into U.S. cannabis markets through its subsidiary, Canopy USA [1]. Group 2: Industry Context - The announcement from the Trump administration suggests a potential shift in cannabis regulation, which could benefit Canadian licensed producers (LPs) like Canopy Growth [1].

Core Viewpoint - Cannabis stocks surged on Monday, with Canopy Growth (CGC.US) and Tilray Brands (TLRY.US) rising nearly 20%, Aurora Cannabis (ACB.US) up nearly 13%, and Cronos Group (CRON.US) increasing by nearly 12% due to reports that Trump is considering reclassifying cannabis as a lower-risk substance [1] Group 1 - Canopy Growth (CGC.US) experienced a significant price increase of nearly 20% [1] - Tilray Brands (TLRY.US) also saw a rise of nearly 20% [1] - Aurora Cannabis (ACB.US) rose nearly 13% [1] - Cronos Group (CRON.US) increased by nearly 12% [1] Group 2 - The surge in cannabis stocks is linked to a report from The Wall Street Journal regarding Trump's potential reclassification of cannabis [1]

Financial Data and Key Metrics Changes - Canopy Growth reported a cannabis net revenue of CAD 57 million, representing a 24% year-over-year increase [20] - Adjusted EBITDA loss was CAD 8 million, compared to a loss of CAD 5 million in the prior year, primarily due to lower gross margins [27] - Cannabis gross margin in Q1 was 24%, down from the previous year, attributed to higher production costs and softer sales in high-margin markets [22][23] Business Line Data and Key Metrics Changes - Canada Medical net revenue grew 13%, marking three consecutive quarters of growth [6] - International net revenues increased by 4%, with Germany showing triple-digit growth [6][21] - Canada adult use net revenue surged 43%, driven by improved distribution and strong consumer demand [11][22] - Stores and Bickel segment revenue decreased by 25% year-over-year, totaling CAD 15 million [24] Market Data and Key Metrics Changes - In Europe, double-digit revenue growth was achieved, particularly in Germany, while Poland faced supply challenges due to regulatory changes [8][21] - The Canadian adult use market saw significant growth, with nearly 4,800 new points of distribution added in Q1 [11] Company Strategy and Development Direction - The company is focused on improving gross margins and achieving positive EBITDA as a company-wide priority [14] - Canopy Growth is enhancing its operational efficiency through cost reduction initiatives, having already achieved CAD 17 million in annualized savings [13][26] - The company is positioning itself for long-term growth in the U.S. market, despite current regulatory challenges [15][46] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to sustain momentum and improve margins in the upcoming quarters [16][30] - The focus remains on operational fundamentals to drive top-line growth and improve gross margins [30] Other Important Information - The company has secured CAD 144 million in cash and short-term investments, with a debt balance of CAD 295 million [29] - Canopy USA has secured USD 20 million in funding to support operations and streamline costs [16][30] Q&A Session Summary Question: Can you speak to some of the drivers of gross margin improvement? - Management expects to exit the year with margins in the low to mid-thirties, driven by efficiency improvements and prioritizing supply to profitable markets [35] Question: Can you elaborate on the supply challenges in Poland? - The company is focusing on internal processes to improve flower allocation, which previously hindered success in the Polish market [39] Question: What other European markets are promising for growth? - Management highlighted the importance of establishing the right infrastructure in Germany and Poland, with significant growth potential in these markets [44] Question: What momentum is building in the U.S. regarding rescheduling? - While not commenting directly on rescheduling, management noted increasing demand and infrastructure in select U.S. geographies [46]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive's content includes insights across various sectors such as biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive is committed to adopting technology to enhance workflows and improve content production [4] - The company utilizes automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Canopy Growth Corporation (CGC) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.37 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +6.67%. A quarter ago, it was expected that this company would post a loss of $0.1 per share when it actually produced a loss of $0.94, delivering a surprise of -840%.Over the last four quarters, the company has ...